Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery

Table 1 Clinicopathological characteristics of gastric cancer patients according to the Cancer Genome Atlas classification

Variables		EBV	MSI	CIN	GS	P value
		n = 30 (10.5%)	n = 58 (20.2%)	n = 179 (62.2%)	n = 20 (7%)
Age (yr)						0.017
	mean (± SD)	61.4 (11.2)	65.9 (12.5)	60.1 (11.7)	60.6 (12.8)
Sex						0.101
	Male	23 (76.7)	29 (50)	103 (57.5)	13 (65)
	Female	7 (23.3)	29 (50)	76 (42.5)	7 (35)
ASA Classification						0.753
	I/II	27 (90)	50 (85.2)	160 (89.4)	19 (95)
	III/IV	3 (10)	8 (13.8)	19 (10.6)	1 (5)
Charlson–Deyo comorbidity index						0.011
	< 5	19 (63.3)	23 (39.7)	112 (62.6)	14 (70)
	≥ 5	11 (36.7)	35 (60.3)	67 (37.4)	6 (30)
Tumor site						0.004
	Upper	8 (26.7)	6 (10.3)	18 (10.1)	2 (10)
	Middle	7 (23.3)	8 (13.8)	34 (19)	3 (15)
	Lower	11 (36.7)	44 (75.9)	123 (68.7)	13 (65)
	Entire	4 (13.3)	0 (0)	4 (2.2)	2 (10)
Type of resection						< 0.001
	Subtotal	8 (26.7)	45 (77.6)	110 (61.5)	11 (55)
	Total	22 (73.3)	12 (22.4)	69 (38.5)	9 (45)
Macroscopic type						0.244
	I /II	9 (34.6)	19 (34.5)	37 (22.7)	4 (21.1)
	III/IV	17 (65.4)	36 (65.5)	126 (77.3)	15 (78.9)
Tumor size (cm)						0.029
	mean (± SD)	6.3 (4.4)	5.3 (2.9)	4.5 (3.0)	5.2 (2.9)
Histological differentiation						0.001
	Well/moderately	8 (26.7)	28 (48.3)	89 (49.7)	2 (10)
	Poorly differentiated	22 (73.3)	30 (51.7)	90 (50.3)	18 (90)
Laurén type						< 0.001
	Intestinal	11 (36.7)	34 (58.6)	88 (49.2)	3 (15)
	Diffuse/mixed	12 (40)	22 (37.9)	88 (49.2)	16 (80)
	Undetermined	7 (23.3)	2 (3.4)	3 (1.7)	1 (5)
Tumor invasion						0.277
	pT1/pT2	10 (33.3)	29 (50)	70 (39.1)	6 (30)
	pT3/pT4	20 (66.7)	29 (50)	109 (60.9)	15 (70)
pN status						0.147
	pN negative	14 (46.7)	32 (55.2)	73 (40.8)	6 (30)
	pN positive	16 (53.3)	26 (44.8)	106 (59.2)	14 (70)
Lymphatic invasion						0.156
	Absent	16 (53.3)	22 (37.9)	96 (53.6)	8 (40)
	Present	14 (46.7)	36 (62.1)	83 (46.4)	12 (60)
Venous Invasion						0.300
	Absent	22 (73.3)	35 (60.3)	125 (69.7)	11 (55)
	Present	8 (26.7)	23 (39.7)	54 (30.3)	9 (45)
Perineural invasion						0.267
	Absent	14 (46.7)	36 (62.1)	91 (50.8)	8 (40)
	Present	16 (53.3)	22 (37.9)	88 (49.2)	12 (60)
Peritumoral inflammatory infiltrate						< 0.001
	Absent/mild	8 (26.7)	35 (60.3)	131 (73.2)	17 (85)
	moderate/intense	22 (73.3)	23 (39.7)	48 (26.8)	3 (15)
pTNM stage						0.014
	I/II	18 (60)	40 (69)	93 (52)	6 (30)
	III/IV	12 (40)	18 (31)	86 (48)	14 (70)

ASA: American Society of Anesthesiologists; CIN: Chromosomal instability; EBV: Epstein-Barr virus; GS: Genomically stable; MSI: Microsatellite instability; SD: Standard deviation.